Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients

Atopic Dermatitis

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Br J Dermatol.

Tsianakas A, Luger TA, Radin A

doi: 10.1111/bjd.15905.

Atopic Dermatitis

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Dermatol Ther (Heidelb).

Simpson EL

doi: 10.1007/s13555-017-0181-6.

Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials

J Am Acad Dermatol.

Fleming P, Drucker AM

doi: 10.1016/j.jaad.2017.09.052.

Atopic Dermatitis

Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ)

Br J Dermatol.

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B

doi: 10.1111/bjd.16156.

COMMENTED

Atopic Dermatitis

The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomised, Double-Blind, Placebo-Controlled Study

Br J Dermatol.

Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E

doi: 10.1111/bjd.17932.

Atopic Dermatitis

Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

J Investig Allergol Clin Immunol.

Nettis E, Ferrucci SM, Ortoncelli M, Pellacani G, Foti C, Di Leo E, Patruno C, Rongioletti F, Argenziano G, Macchia L, Tavecchio S, Napolitano M, Ribero S, Bonzano L, Romita P, Di Bona D, Nisticò SP, Piras V, Calabrese G, Detoraki C, Carbonara M, Fabbrocini G

doi: 10.18176/jiaci.0641.

Atopic Dermatitis

Increased risk of cutaneous and systemic infections in atopic dermatitis - A cohort study.

J Invest Dermatol.

Langan SM, Abuabara K, Henrickson SE, Hoffstad O, Margolis DJ

doi: 10.1016/j.jid.2017.01.030.

Atopic Dermatitis

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis

JAMA Dermatol.

Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Küster D, Siegels D, Schmitt J, Flohr C

doi: 10.1001/jamadermatol.2020.0796.

Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Lancet.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B

doi: 10.1016/

Related content

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials

Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ)

The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomised, Double-Blind, Placebo-Controlled Study

Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Increased risk of cutaneous and systemic infections in atopic dermatitis - A cohort study.

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial